The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
https://www.linkedin.com/posts/capital-access_investorrelations-corporateaccess-investmentmanagement-activity-6889121847758131203-8xoK
Avacta bringing on a new investor relations company....
https://www.capitalaccessgroup.co.uk/
ABOUT US
Capital Access Group is a specialist investor relations advisory business that connects quoted and private companies with new and existing investors, primarily private client fund managers, smaller institutions and regional pension funds
We do this by targeting, meeting and talking to investors.
Our service is unconstrained by MiFID II, is additive to your existing corporate broker and ultimately looks to broaden your share register and in turn increase liquidity, dampen volatility and enhance share price performance.
Interesting timing after todays new, low ball bids must be a major worry for the company right now.
Takeda will be looking very very closely at AVA3996 imo.
I actually think Avacta will ever to drive 6000 as deep as possible into the clinic and will look to licence other Precision drugs.
I’m sure Takeda will be willing to stump up a very healthy upfront payment for 3996.
Exactly Bella, if early AVA6000 was poor they would they paused the 3996 program.
This really is mega news in my book, following IND approval for 6000 i’m now even more confident the Precision chemistry is working.
What an opportunity Avacta has in front of it:)
Great news and lovely to see after the last week obviously:)
That RNS definitely reads as the Precision Chemistry is absolutely working in humans to me anyway.
Love this bit….,
“If AVA3996 is shown to have a significantly improved safety profile in the clinic, then not only could it provide a better tolerated treatment for multiple myeloma, but it has the potential to be the first proteasome inhibitor to be suitable for treating solid tumours, thereby significantly increasing the market”
GLA
Great post EGTP and mirrors my thoughts on why Richard Hughes especially founded Medusa19. The guy is one of the best deal makers around, and im led to believe very good at spotting future trends. His investment record speaks for itself and he’s holds almost 3% of Avacta for good reason.
On the other side of the fence, Avacta have identified rapid POC diagnostics as a key area of focus for the Wetherby business unit. Medusa19 will be a key partner in marketing AffiDX tests to a global audience, effectively becoming the retail arm of Avacta, allowing Al and his team to focus on the science - a great move by Avacta imo.
I think I said it before Xmas, but the M19/Avacta goes way beyond Covid. We’ve had a minor set back, but I still expect this to be a very rewarding tie up for Avacta shareholders.
Yes that’s absolutely true, it was the antibody that failed.
My post was absolutely not about Affimers failing in AffiDX, it was just some general thoughts following the bruising week we’ve just had, which WAS absolutely not the fault of the Affimer platform.
Naturally after a week like we’ve had doubts may start to creep in about wether the technology can truly compete with antibodies. Well, I’ve spent the last few days going back through my research and I still can’t find any reasons why the Affimer technology can’t compete in all the fields Antibodies operate in.
The facts are that Affimers have great binding affinity typically in the nanomolar range, similar to antibodies. There incredibly specific, easy to produce, are stable, have low cost of manufacture and have freedom to operate around antibody IP. However, the company does need to do a better job of commercialising the technology and I’d certainly like to see more deals like the Astrea and Biokit. I suspect we will also see the next AffiDX product launched in 2022 for Cortisol(stress). I’m happy that the company is now pushing ahead with its own products now as the licensing route is far too slow.
On the therapeutics side, Affimers have demonstrated the necessary properties for a therapeutic platform. The animal studies for the PD-L1 Affimer absolutely proved that they can inhibit tumour growth, they actually performed as well as marketed antibodies The only issue I could find during my research was half-life properties with rapid kidney clearance. However the Affimer XT progress has seemingly solved this issue, clearly LG think so and are now in pre-clinical development with a PD-L1/XT bi-specific Affimer.
Regardless of the past week I’m still hugely excited about what the Affimer platform and it’s potential to compete with antibodies in all fields. Of course we also have Precision which potentially addresses an even bigger market and nothing has made me worry on that front yet. All we’ve had since 1st dosing, is Al telling us he’s pleased with progress, extra hospitals opening up and IND approval, the submission would have had to include early data from the 1st patient. I do however believe that AVA600 is running several weeks late due to covid, but we could get news on that any day now.
Anyway a bruising week, but if there is one share that can easily recover from these setbacks it’s Avacta.
GLA.
Morning All,
Not gonna lie, I'm absolutely gutted this this mornings announcement, I certainly didn't see that coming and neither did any sources I trust. Unfortunately I can see a length delay in getting the test back on the market, what's really frustrating though is that this isn't even the fault of the Affimer technology.
Clearly in the short term our best chance of seeing a recovery in the share price will be AVA6000. Nothing so far has made me have any worries in that regard and the silence on this side of business should be looked at more favourably than diagnostics imo. The IND approval settled a lot of nerves here, but after this morning I can certainly appreciate peoples concerns.
Going back to AffiDX, with the bad news out of the way and the UK avenues seemingly blocked for good, I hope the company takes its time and take a holistic approach to version 2. We cant afford anymore slip ups and so much more will be known about the Sars-Cov-2 virus now. Maybe we look again at the Mologic/AffiDX combo test and possible saliva also, the evidence is certainly pointing going that way. Either way we need to get it right this time and the opportunity will certainly still be around for years to come imo.
Anyway not good news at all today and management certainly have a job on their hands restoring credibility. But the main event is still ahead of us and an certainly not selling a single share until I see that data, the RR is worth it imo.
It’s a complete waste of time, Al knew it back in April and focussed away from the UK.
Why focus on this little island when their bigger fish to go after. Richard Hughes will get the job done, but some serious scars have been created by this useless Government.
Medusa19 and Avacta have been focussed away from the UK months. The UK scientists don’t wa t to admit their wrong about their validation processes. That’s fine we will sell elsewhere then.
Maybe this is Medusa’s sales pitch to the FDA……..fancy making the UK regulators look a bit silly:)
FDA have absolutely no time for frozen samples, pig spit or running validation tests off label.
Also very fair comments Eastside.
Ultimately the time for judging Avacta's faith in Medusa19 will be the end of Q1. By that point they will have ample time to demonstrate they can be Avacta's retail partner for diagnostics. I'm firmly in the camp this is the perfect tie up for Avacta, but we need to see the results over the coming weeks.
That's true and I'm sure Medusa will address it in the coming days.
But lets not be too harsh on them please. Medusa19 beat some major diagnostics companies to self test approval in Europe, for a start up that was truly an impressive feat and with new tech under the bonnet too!
Was literally just about to say the same thing.
The focus will be Governments until they stop buying and allow the consumer market to develop. The website can take a back seat for now, focus right now is on supply chain and massive upscaling to meet the huge demand out there.